flow trial semaglutide kidney outcomes nejm 2024 hazard ratio clinical (funded by Novo Nordisk): showed 24% reduction in the risk of disease-related events in people with type 2 diabetes and chronic kidney disease compared to placebo. Investigators Top Stories in Nephrology 2024
Pay in 4 interest-free payments of $6.39 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Nov 21 - Nov 26








![Physiologic effects of GLP-1 (adapted from Granata et al. [11])](https://www.researchgate.net/publication/359199250/figure/fig1/AS:11431281081130351@1661532031197/Physiologic-effects-of-GLP-1-adapted-from-Granata-et-al-11.png)















